I think it's a major step forward. There's no question about it.
In our trial, women who received part of their chemotherapy via an IP route had a median survival time of 16 months longer than women who received only IV chemotherapy.
This is the longest survival reported to date for advanced ovarian cancer.
But now we have firm data showing we should use (it) in most women with advanced ovarian cancer who have had successful surgery to remove the bulk of their tumor.
